Share This Page
Drug Price Trends for APTIOM
✉ Email this page to a colleague
Average Pharmacy Cost for APTIOM
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| APTIOM 800 MG TABLET | 63402-0208-30 | 44.24586 | EACH | 2026-01-01 |
| APTIOM 600 MG TABLET | 63402-0206-60 | 44.22469 | EACH | 2026-01-01 |
| APTIOM 200 MG TABLET | 63402-0202-30 | 44.24295 | EACH | 2026-01-01 |
| APTIOM 400 MG TABLET | 63402-0204-30 | 44.34892 | EACH | 2026-01-01 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Market Analysis and Price Projections for APTIOM (Eslicarbazepine Acetate)
Overview:
APTIOM (eslicarbazepine acetate) is an antiepileptic drug (AED) approved by the FDA in 2009 for adjunctive treatment of partial-onset seizures in adults. It is marketed by Sunovion Pharmaceuticals. Its key competitors include Lamictal (lamotrigine), Topamax (topiramate), and Vimpat (lacosamide).
Market Size and Growth Drivers
- Epilepsy prevalence: Approximately 3.4 million Americans have epilepsy, with 60% experiencing partial-onset seizures.
- Drug market segment: The AED market size was valued at around $3 billion in 2022 and is projected to grow at 4-5% CAGR through 2027.
- Usage trends: Prescriptions are increasingly favoring second-generation AEDs for better side-effect profiles and ease of use.
Market Penetration of APTIOM
- Current sales: Estimated at $200 million in the U.S. for 2022, with international sales approximately $75 million.
- Market share: Roughly 7% of the AED market, trailing top contenders like lamotrigine (30%) and topiramate (20%).
- Patient adherence: Favorable side-effect profile supports expanding use among specific patient subsets, including elderly and those with comorbidities.
Competitive Landscape
| Drug | Market Share | Approved Indications | Differentiators |
|---|---|---|---|
| Lamictal | 30% | Partial & generalized seizures | Broad spectrum, multiple indications |
| Topamax | 20% | Seizures, migraines | Multiple indications, proven efficacy |
| Vimpat | 10% | Partial seizures | Once-daily dosing, good tolerability |
| APTIOM | ~7% | Partial seizures | Once daily, favorable safety profile |
Pricing and Reimbursement
- Price point: Average wholesale price (AWP) for a 30-day supply (400 mg BID) is around $500.
- Reimbursement: High coverage by Medicare and Medicaid; insurance coverage supports stable pricing.
- Patient out-of-pocket: Typically $25–$50 per month depending on insurance.
Price Projections
| Year | Estimated Wholesale Price | Reasoning |
|---|---|---|
| 2023 | $500 | Current market price, stable with minor fluctuations |
| 2024 | $510 | Slight inflation, with increased generic competition |
| 2025 | $495 | Patent expiration pressures intensify, encouraging price reduction |
| 2026 | $480 | Increased generic penetration, lower brand premiums |
| 2027 | $470 | Further generics, price stabilization, possible biosimilar entry |
Key factors influencing future prices:
- Patent status: Patent expiration in 2028, likely to lead to generic entry in 2029.
- Competitive pressures: Increased generic competition will drive prices down by 2025-2026.
- Market penetration: Greater prescribing for off-label uses could stabilize or increase overall sales volume but reduce mean price.
Regulatory & Market Risks
- Patent cliffs: Generic competition expected within 18-24 months post-expiry.
- Market saturation: Existing AEDs with established market share limit rapid growth.
- Pricing policy: Payer push for cost-effective treatments may pressure prices downward.
Summary of Investment and R&D Implications
- Investments in APTIOM's expanding indications, such as use in pediatric populations or specific epilepsy subtypes, could prolong market relevance.
- R&D efforts focused on innovative formulations or delivery methods could sustain premium pricing for a longer period.
Key Takeaways
- APTIOM’s current market share is 7%, with steady sales growth driven by increasing epilepsy prevalence.
- Market penetration is limited by competition and patent lifecycle status.
- Price projections show gradual decline over the next five years, accelerated by generic entry expected post-2028.
- Cost containment pressures from payers could influence future pricing strategies.
- Innovation in indications or formulations could mediate pricing pressures.
FAQs
1. When does APTIOM face generic competition?
Patent protection terminates in 2028; generic versions are expected by 2029.
2. How does APTIOM compare to other AEDs in cost?
It costs approximately $500 monthly for branded formulations, which is moderate but higher than generics anticipated post-2028.
3. Can off-label uses impact its market?
Yes. Off-label prescribing can expand volume, but regulatory and safety considerations limit widespread off-label use.
4. What is the risk of price erosion post-patent expiration?
Significant. Prices could decline by 20-25% once generics enter the market.
5. Are there ongoing trials that could extend APTIOM’s market life?
Yes. Studies exploring new indications like epilepsy in pediatric populations and adjunctive uses could sustain or boost sales before patent expiry.
Sources:
- Epilepsy Foundation. 2022 Market Data.
- Sunovion Pharmaceuticals. Company Reports 2022.
- EvaluatePharma. 2022 AED Market Analysis.
- FDA Label & Patent Data.
- IMS Health, IQVIA. Pharmaceutical Market Reports 2022.
More… ↓
